Results 161 to 170 of about 148,662 (310)

ProteinDJ: A high-performance and modular protein design pipeline. [PDF]

open access: yesProtein Sci
Silke D   +6 more
europepmc   +1 more source

Tumor mutational burden as a determinant of metastatic dissemination patterns

open access: yesMolecular Oncology, EarlyView.
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal   +4 more
wiley   +1 more source

Dynamic Binder Exchange Improves Protein Labeling Efficiency in DNA-PAINT up to 15-Fold. [PDF]

open access: yesAngew Chem Int Ed Engl
Steinek C   +5 more
europepmc   +1 more source

Corrigendum to “Synthesis and characterization of eco-friendly mortars made with RHA-NaOH activated fly ash as binder at room temperature” [Clean. Mater. 1 (2021) 100010]

open access: gold, 2022
Juvenal Giogetti Deutou Nemaleu   +6 more
openalex   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

open access: yesMolecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat   +8 more
wiley   +1 more source

Bio-synthesized TiO2 nanoparticles and the aqueous binder-based anode derived thereof for lithium-ion cells [PDF]

open access: diamond
Akhilash Mohanan Pillai   +6 more
openalex   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

open access: yesMolecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy